Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.56
+0.65 (7.30%)
At close: Mar 4, 2026, 4:00 PM EST
9.48
-0.08 (-0.84%)
After-hours: Mar 4, 2026, 7:36 PM EST
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Vir Biotechnology stock have an average target of 19.63, with a low estimate of 12 and a high estimate of 30. The average target predicts an increase of 105.33% from the current stock price of 9.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vir Biotechnology stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +109.21% | Mar 4, 2026 |
| Barclays | Barclays | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +213.81% | Feb 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $24 | Buy | Maintains | $20 → $24 | +151.05% | Feb 24, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $12 → $18 | Buy | Maintains | $12 → $18 | +88.28% | Feb 24, 2026 |
| Needham | Needham | Strong Buy Maintains $14 → $18 | Strong Buy | Maintains | $14 → $18 | +88.28% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
7.12M
from 68.56M
Decreased by -89.62%
Revenue Next Year
72.99M
from 7.12M
Increased by 925.73%
EPS This Year
-2.72
from -3.16
EPS Next Year
-2.24
from -2.72
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 12.6M | 192.7M | |||
| Avg | 7.1M | 73.0M | |||
| Low | 1.9M | 11.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -81.6% | 2,607.7% | |||
| Avg | -89.6% | 925.7% | |||
| Low | -97.2% | 65.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.16 | -1.55 | |||
| Avg | -2.72 | -2.24 | |||
| Low | -3.56 | -2.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.